In a world where respiratory issues are increasingly common, finding practical solutions can be daunting. Breathe Drops ...
Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...
Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
16h
Pharmacies in the UK face significant cuts, so it’s perhaps not surprising that they sell many unevidenced lifestyle products ...
The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...
The parents of a 22-year-old Wisconsin man who died after an asthma attack have filed a lawsuit against Walgreens and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback